Forward P/E means nothing when Insiders have sold all but less than 1% of their shares. No upside left, just distribution by institutional holders who bought well below $100.
A lot of retail bag holders will buy this hoping and praying ..........!
All insider selling is pre-scheduled. Insiders hold lots of options and sell when they exercise to diversify their portfolios. I'd be more worried if this was a small cap with no earnings and insiders were selling. With a P/E under 20, this is a real company with real earnings and okay - excellent growth prospects... and the products they sell are not dependent on discretionary spending. Can't help but feel there is excessive pessimism around this stock... and that bolsters a bull case scenario.
Michael Yee ( RBC Analyst ) Best In Business- Good Link
Sentiment: Strong Buy
Ridiculously how oversold this is / will be a dip in the chart that everyone will wish they bought at.
Sentiment: Strong Buy
Look at all the insider selling from $300-$475 as another poster pointed out. Corporate insiders own next to nothing, certainly under 1%. No 13Ds either. Perhaps the parabolic rise was the extreme.
Wow. I just noticed that. Corporate insiders own next to nothing. They've been ringing the register all year while given strong guidance. Seems pretty deceptive and manipulative to me. No 13Ds either so it's all passive mutual fund investors.
Avxl had the goods at AAIC last week. Bibb is a good long term hold. AVXL is a screaming buy!
Aducanumab, if successful in Phase III testing, will not be available until 2018 or 2019. In the near-term BIIB can only boost revenue and share value through strategic acquisition.
with a forward P/E of about 16, and PEG ratio a little above 1, perhaps
some will view BIIB as a biotech "value stock"?
To me the selling seemed extreme, so perhaps it'll see a reversal
of fortune on Monday....
For the record, I have never owned BIIB before Friday, when I bought in
4 increments as it dropped.
It is in Phase 3 and will be on the market next year. BIIB went through the roof when this drug was simply announced to be in testing. Analysts say this could DOUBLE the company's revenue and earnings. You do the math. $300 will be so far in the rear-view mirror next year, it will seem like $30.